Search Prime Grants

HT94252310451

Project Grant

Overview

Grant Description
First in class peptidomimetic drug for the treatment of TBI and sequelae nonclinical safety assessment.
Awardee
Alcamena Stem Cell Therapeutics
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Awarding / Funding Agency
Defense Health Agency (DHA) [DoD]
Place of Performance
Halethorpe, Maryland 212273863 United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Alcamena Stem Cell Therapeutics was awarded Project Grant HT94252310451 worth $1,700,000 from Defense Health Agency in July 2023 with work to be completed primarily in Halethorpe Maryland United States. The grant has a duration of 2 years and was awarded through assistance program 12.420 Military Medical Research and Development.

Status
(Complete)

Last Modified 7/11/23

Period of Performance
7/1/23
Start Date
6/30/25
End Date
100% Complete

Funding Split
$1.7M
Federal Obligation
$0.0
Non-Federal Obligation
$1.7M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to HT94252310451

Additional Detail

Award ID FAIN
HT94252310451
SAI Number
None
Award ID URI
None
Awardee Classifications
For-Profit Organization (Other Than Small Business)
Other
Awarding Office
HT9425 ARMY MED RES ACQ ACTIVITY
Funding Office
HT9425 ARMY MED RES ACQ ACTIVITY
Awardee UEI
J6DAAQH7AQL8
Awardee CAGE
7B1Q9
Performance District
07
Senators
Benjamin Cardin
Chris Van Hollen
Representative
Kweisi Mfume

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
Defense Health Program, Defense (097-0130) Department of Defense-Military Grants, subsidies, and contributions (41.0) $1,700,000 100%
Modified: 7/11/23